CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02452554
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:20.838950+00:00
Published At: 2019-08-29T00:00:00+00:00
Record Updated At: 2022-01-13
Results Posted At: 2019-08-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pleuropulmonary Blastoma", "Recurrent Malignant Peripheral Nerve Sheath Tumor", "Recurrent Neuroblastoma", "Recurrent Rhabdomyosarcoma", "Recurrent Synovial Sarcoma", "Wilms Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-01-13"
protocolSection.identificationModule.nctId: "NCT02452554"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-08-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.